Suppr超能文献

前列腺混合性腺癌、肉瘤样癌和腺鳞癌:一例报告。

Mixed adenocarcinoma, sarcomatoid carcinoma and adenosquamous carcinoma of the prostate: A case report.

作者信息

Zhang Zhongfu, Wang Yadong, Zhao Qing, Li Ganhong, Zhao Xingqi, Li Jun, Li Xianxin

机构信息

Department of Urological Surgery, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518036, P.R. China.

Department of Urology, Zunyi Medical College Fifth Affiliated Hospital, Zhuhai, Guangdong 519100, P.R. China.

出版信息

Oncol Lett. 2014 Nov;8(5):2325-2327. doi: 10.3892/ol.2014.2493. Epub 2014 Sep 1.

Abstract

Adenosquamous carcinoma (ASC) and sarcomatoid carcinoma (SC) of the prostate are rare, but highly aggressive tumors. The occurrence of mixed carcinomas in the prostate is even more rarely reported. The present study reports the case of a 62-year-old male who was diagnosed with prostatic adenocarcinoma accompanied by multiple bone metastases, as shown by a needle biopsy and skeletal computed tomography scan. The patient was treated with hormonal therapy, but thereafter, specimens from a transurethral resection of the prostate (TURP) were found to be composed of three histologically distinct elements: ASC, SC and adenocarcinoma. The level of p53 was evaluated by immunohistochemistry in detail, and it was found that this was significantly increased in the TURP samples compared with the needle biopsy samples. The abnormal level of p53 was likely associated with the prognosis of the patient; the patient succumbed to prostate carcinoma two months after the confirmation of the diagnosis.

摘要

前列腺腺鳞癌(ASC)和肉瘤样癌(SC)较为罕见,但具有高度侵袭性。前列腺混合癌的发生则报道得更为罕见。本研究报告了一例62岁男性患者,经穿刺活检和骨骼计算机断层扫描显示,其被诊断为伴有多处骨转移的前列腺腺癌。该患者接受了激素治疗,但之后经尿道前列腺切除术(TURP)的标本发现由三种组织学上不同的成分组成:ASC、SC和腺癌。通过免疫组织化学详细评估了p53水平,发现与穿刺活检样本相比,TURP样本中的p53水平显著升高。p53水平异常可能与患者的预后相关;确诊两个月后,该患者死于前列腺癌。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f42/4186607/a8e40fc0024a/OL-08-05-2325-g00.jpg

相似文献

1
Mixed adenocarcinoma, sarcomatoid carcinoma and adenosquamous carcinoma of the prostate: A case report.
Oncol Lett. 2014 Nov;8(5):2325-2327. doi: 10.3892/ol.2014.2493. Epub 2014 Sep 1.
2
Sarcomatoid carcinoma of the prostate: a study of 42 cases.
Am J Surg Pathol. 2006 Oct;30(10):1316-21. doi: 10.1097/01.pas.0000209838.92842.bf.
4
Prostate carcinoma with squamous differentiation: an analysis of 33 cases.
Am J Surg Pathol. 2004 May;28(5):651-7. doi: 10.1097/00000478-200405000-00014.
5
Sarcomatoid carcinoma of the prostate with bladder invasion shortly after androgen deprivation: Two case reports.
World J Clin Cases. 2021 Mar 6;9(7):1668-1675. doi: 10.12998/wjcc.v9.i7.1668.
7
Sarcomatoid carcinoma of the prostate: a case report.
Int J Clin Exp Pathol. 2010 Feb 5;3(3):319-22.
10
Rare Histological Variants of Prostate Adenocarcinoma: A National Cancer Database Analysis.
J Urol. 2020 Aug;204(2):260-266. doi: 10.1097/JU.0000000000001011. Epub 2020 Mar 6.

引用本文的文献

1
Sarcomatoid prostate carcinoma: a case report.
BMC Urol. 2025 Apr 25;25(1):104. doi: 10.1186/s12894-025-01790-y.
2
Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report.
BMC Med Genomics. 2021 Sep 3;14(1):217. doi: 10.1186/s12920-021-01068-w.
3
Sarcomatoid Carcinoma in the Head and Neck: A Population-Based Analysis of Outcome and Survival.
Laryngoscope. 2021 Feb;131(2):E489-E499. doi: 10.1002/lary.28956. Epub 2020 Jul 21.

本文引用的文献

1
Predictive value of p53 expression in the risk of malignant gastrointestinal stromal tumors: Evidence from 19 studies.
Exp Ther Med. 2012 Jan;3(1):87-92. doi: 10.3892/etm.2011.369. Epub 2011 Oct 19.
2
Cancer treatment and survivorship statistics, 2012.
CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41. doi: 10.3322/caac.21149. Epub 2012 Jun 14.
3
p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53.
Cell Death Differ. 2011 Sep;18(9):1487-99. doi: 10.1038/cdd.2011.81. Epub 2011 Jul 15.
4
Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.
Mol Cancer Res. 2011 Mar;9(3):271-9. doi: 10.1158/1541-7786.MCR-10-0496. Epub 2011 Feb 22.
5
Rare and unusual histological variants of prostatic carcinoma: clinical significance.
BJU Int. 2008 Nov;102(10):1369-74. doi: 10.1111/j.1464-410X.2008.08074.x. Epub 2008 Sep 12.
6
Clinical significance of p53 alterations in surgically treated prostate cancers.
Mod Pathol. 2008 Nov;21(11):1371-8. doi: 10.1038/modpathol.2008.104. Epub 2008 Jun 13.
7
EAU guidelines on prostate cancer.
Eur Urol. 2008 Jan;53(1):68-80. doi: 10.1016/j.eururo.2007.09.002. Epub 2007 Sep 19.
8
Sarcomatoid carcinoma of the prostate: a study of 42 cases.
Am J Surg Pathol. 2006 Oct;30(10):1316-21. doi: 10.1097/01.pas.0000209838.92842.bf.
9
Unusual subtypes of prostate cancer.
Mod Pathol. 2004 Mar;17(3):316-27. doi: 10.1038/modpathol.3800052.
10
The p53 pathway.
J Pathol. 1999 Jan;187(1):112-26. doi: 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验